올릭스

226950KOSDAQ

45.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Olix is a biopharmaceutical company specializing in developing therapeutic drugs for difficult-to-treat diseases using RNA interference (RNAi) platform technology. The company leverages its proprietary 'self-delivering asymmetric siRNA (cp-asiRNA)' technology to create drug candidates targeting metabolic diseases, obesity, and cardiovascular conditions. Through technology licensing agreements with global and domestic pharmaceutical companies, including a significant deal with Eli Lilly, Olix has established a strong market presence and revenue streams.

Number of Employees

76people

Average Salary

198.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

15.96Industry Average 1.200.0Point

13.3x industry avg (risky)

ROE

-18.68Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

15.97Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲45.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼33.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -56.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 104,700Won52-week high 207,00052-week low 85,100

1-month return2.0Point

1m -5.59% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기업설명회(IR)개최2026-10-14
Neutral투자판단관련주요경영사항 (임상시험계획 승인 신청 반려)2026-10-12
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (안드로겐성 탈모가 있는 건강한 남성을 대상으로 OLX72021의 안전성과 유효성을 평가하기 위한 다기관, 무작위 배정, 이중 눈가림, 위약 대조, 다중 상승 용량 제1b/2a상 임상시험 계획 승인)2026-10-08
Neutral기업설명회(IR)개최2026-10-06
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청)2026-09-30